Incyte reported that the Phase III frontMIND trial showed adding tafasitamab plus lenalidomide to R‑CHOP reduced the risk of progression or death by 25% versus R‑CHOP alone in high‑risk DLBCL/HGBL. Absolute PFS gains were 8.2% at two years and 6.6% at three years, and MRD‑negativity rates were higher with the combination (81.3% vs 66.7%). The trial enrolled 899 patients, showed benefits across prespecified subgroups, improved event‑free survival, and demonstrated an expected safety profile dominated by neutropenia, anemia and peripheral neuropathy.
Incyte: Tafasitamab + Lenalidomide With R‑CHOP Cuts Progression Risk 25% in Phase III frontMIND for High‑Risk DLBCL/HGBL
The trial data demonstrated a 25% reduction in risk of disease progression or death with Tafa-Len-R-CHOP versus R-CHOP. Credit: MrWinn / Shutterstock.com.(MrWinn / Shutterstock.com.)
Incyte reported positive topline results from the pivotal Phase III frontMIND trial evaluating tafasitamab (Monjuvi/Minjuvi) combined with lenalidomide and R‑CHOP — a regimen described by the company as Tafa‑Len‑R‑CHOP — as first‑line therapy for adults with previously untreated, high‑risk diffuse large B‑cell lymphoma (DLBCL) or high‑grade B‑cell lymphoma (HGBL).
Trial Design
The double‑blind, randomized, placebo‑controlled study enrolled 899 adults who met high‑risk criteria by International Prognostic Index (IPI): an IPI score of 3–5, or an age‑adjusted IPI of 2–3 for patients aged 60 years or younger. Progression‑free survival (PFS) by Lugano 2014 criteria was the primary endpoint; secondary endpoints included event‑free survival and overall survival.
Key Efficacy Findings
Tafa‑Len‑R‑CHOP reduced the risk of disease progression or death by 25% versus standard R‑CHOP alone. Absolute PFS gains were reported as 8.2% at two years and 6.6% at three years in favor of the tafasitamab combination. The benefit was observed across all prespecified subgroups, including lymphoma and molecular (cell‑of‑origin) subtypes.
Minimal residual disease (MRD) negativity rates were higher in the tafasitamab arm (81.3%) compared with R‑CHOP alone (66.7%). Event‑free survival also improved significantly, and an interim analysis showed a trend toward improved overall survival.
Steven Stein, Incyte executive vice‑president and chief medical officer, commented that the frontMIND data "reinforce the potential of Tafa‑Len‑R‑CHOP to meaningfully change the first‑line treatment landscape for patients with high‑risk DLBCL or HGBL," noting encouraging efficacy across prespecified subgroups.
Safety And Tolerability
The regimen was generally well tolerated and showed a safety profile consistent with expectations when combining an anti‑CD19 antibody, an immunomodulatory agent and R‑CHOP. The most common treatment‑emergent adverse events were neutropenia (70.7%), anemia (46.3%) and peripheral neuropathy (40.6%). Overall rates of study drug discontinuation were similar between the Tafa‑Len‑R‑CHOP and R‑CHOP cohorts.
Implications
With a meaningful reduction in progression or death and broad subgroup benefit, Incyte positions the combination as a potential new first‑line option for patients with high‑risk DLBCL/HGBL. Confirmation of an overall survival benefit and regulatory/reimbursement paths will determine how quickly this regimen could be adopted in practice.
Note: These are company‑reported topline results. Full data, peer review and regulatory submissions will be needed to validate and contextualize the findings.
Help us improve.
